文献速递乳腺癌

德系犹太人女性中BRCA1和BRCA2始祖等位基因以外突变所致的乳腺癌遗传易感性

Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
PubMed 文献 · JAMA Oncol · 2017-01-01

该队列研究对1996至2000年纳入纽约乳腺癌研究的1007例德系犹太人浸润性乳腺癌患者进行23个已知及候选乳腺癌基因测序,发现在903例不携带BRCA1/BRCA2始祖突变的患者中,0.8%携带BRCA1/BRCA2其他致病突变,3.4%携带其他乳腺癌基因致病突变。全部遗传易感性中73.8%由BRCA1/BRCA2始祖等位基因导致。作者认为全面测序可为德系犹太人乳腺癌患者提供完整相关遗传信息。

要点

  • 903例无BRCA1/BRCA2始祖突变者中7例(0.8%)携带BRCA1/BRCA2其他致病突变。
  • 903例中31例(3.4%)携带其他乳腺癌基因致病突变:CHEK2 29例,BRIP1和NBN各1例。
  • 全部1007例中142例(14.1%)携带致病性胚系突变,其中BRCA1/BRCA2 111例(11.0%),CHEK2或其他乳腺癌基因31例(3.1%)。

核心结论

  • 全面测序可为德系犹太人乳腺癌患者提供完整相关遗传信息。

研究设计与样本

  • 队列研究,纳入1996至2000年纽约乳腺癌研究(NYBCS)中12家主要癌症中心的1007例首次诊断浸润性乳腺癌且本人及四位祖父母均为德系犹太人的女性。
  • 对全部1007例NYBCS先证者基因组DNA使用BROCA靶向多重基因面板对23个已知及候选乳腺癌基因进行测序。
  • 数据分析时间为2014年7月10日至2017年3月10日。

主要发现

  • 1007例先证者中903例不携带BRCA1或BRCA2始祖突变;其中7例(0.8%)携带BRCA1或BRCA2其他致病突变,31例(3.4%)携带其他乳腺癌基因致病突变(CHEK2 29例,BRIP1和NBN各1例)。
  • NYBCS全部乳腺癌遗传易感性中,73.8%(142例中104例)由BRCA1或BRCA2始祖等位基因导致,4.9%(142例中7例)由BRCA1或BRCA2其他突变导致,21.8%(142例中31例)由其他基因突变导致。
  • 1007例德系犹太人乳腺癌患者中14.1%(142例)携带导致其疾病的胚系突变:11.0%(1007例中111例)位于BRCA1或BRCA2,3.1%(1007例中31例)位于CHEK2或其他乳腺癌基因。
  • 111例BRCA1或BRCA2突变患者中,57例(51.4%)有母亲或姐妹患乳腺癌或卵巢癌,54例(48.6%)没有。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Among Ashkenazi Jewish women, 3 mutations in BRCA1 and BRCA2 severely increase the risk of breast and ovarian cancer. However, among Ashkenazi Jewish patients with breast cancer who do not carry one of these founder mutations, the likelihood of carrying another pathogenic mutation in BRCA1 or BRCA2 or another breast cancer gene is not known. This information would be valuable to the patient and family for cancer prevention and treatment. OBJECTIVE: To determine the frequency of cancer-predisposing mutations other than the BRCA1 and BRCA2 founder alleles among patients of Ashkenazi Jewish ancestry with breast cancer. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, genomic DNA of women from 12 major cancer centers with a first diagnosis of invasive breast cancer who identified themselves and all 4 grandparents as Ashkenazi Jewish and participated in the New York Breast Cancer Study (NYBCS) from 1996 to 2000 was sequenced for known and candidate breast cancer genes. Data analysis was performed from July 10, 2014, to March 10, 2017. MAIN OUTCOMES AND MEASURES: Genomic DNA from all 1007 NYBCS probands was sequenced for 23 known and candidate breast cancer genes using BROCA, a targeted multiplexed gene panel. RESULTS: Of the 1007 probands in the study, 903 probands had no founder mutations in BRCA1 or BRCA2; of these probands, 7 (0.8%) carried another pathogenic mutation in BRCA1 or BRCA2, and 31 (3.4%) carried a pathogenic mutation in another breast cancer gene (29 in CHEK2, and 1 each in BRIP1 and NBN). Of all inherited predispositions to breast cancer in the NYBCS, 73.8% (104 of 142) were due to a BRCA1 or BRCA2 founder allele, 4.9% (7 of 142) to another BRCA1 or BRCA2 mutation, and 21.8% (31 of 142) to a mutation in another gene. Overall, 14.1% (142 of 1007) of Ashkenazi Jewish patients with breast cancer in the NYBCS carried a germline mutation responsible for their disease: 11.0% (111 of 1007) in BRCA1 or BRCA2, and 3.1% (31 of 1007) in CHEK2 or another breast cancer gene. Of the 111 patients with BRCA1 or BRCA2 mutations, 57 (51.4%) had a mother or sister with breast or ovarian cancer and 54 patients (48.6%) did not. CONCLUSIONS AND RELEVANCE: Comprehensive sequencing would provide complete relevant genetic information for Ashkenazi Jewish patients with breast cancer.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Walsh T, Mandell JB, Norquist BM, et al. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. JAMA Oncol. 2017. PMID: 28727877. doi:10.1001/jamaoncol.2017.1996

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。